BY CANCER CLASSIFICATION 96Breast Cancer MDx Platforms 97TABLE 45 BREAST CANCER MDX TECHNOLOGY PLATFORMS 97TABLE 46 STATUS OF ADVANCED BREAST CANCER DIAGNOSTICS 98CERVICAL CANCER 102TABLE 47 STATUS OF ADVANCED HPV DIAGNOSTICS 104COLORECTAL CANCER 106Conventional Colorectal Cancer Screening Tests 107TABLE 48 CURRENT SCREENING AND DIAGNOSTICS TESTS FOR COLORECTALCANCER 107Molecular Colorectal Cancer Diagnostics Tests 108TABLE 49 STATUS OF ADVANCED COLORECTAL CANCER DIAGNOSTICS 108CANCER OF UNKNOWN PRIMARY (CUP) 110TABLE 50 CANCER UNKNOWN PRIMARY INDUSTRY 111KIDNEY CANCER 113TABLE 51 STATUS OF ADVANCED KIDNEY CANCER DIAGNOSTICS 113LEUKEMIA 114TABLE 52 STATUS OF ADVANCED LEUKEMIA DIAGNOSTICS 114LIVER CANCER 116TABLE 53 STATUS OF LIVER CANCER NEXT GENERATION DX TESTS 117LYMPHOMA 118TABLE 54 STATUS OF ADVANCED LYMPHOMA CANCER DIAGNOSTICS 118LUNG CANCER 119TABLE 55 FIVE YEAR SURVIVAL RATES FOR NON SMALL CELL LUNG CANCER (%) 119TABLE 56 STATUS OF ADVANCED LUNG CANCER DIAGNOSTICS 120MELANOMA 124TABLE 57 STATUS OF ADVANCED MELANOMA DIAGNOSTICS 125OVARIAN CANCER 126TABLE 58 EARLY SCREENING OVARIAN CANCER TESTS 126TABLE 59 STATUS OF OVARIAN CANCER NEXT GENERATION DIAGNOSTICS TESTS 127PANCREATIC CANCER 129TABLE 60 STATUS OF ADVANCED PANCREATIC CANCER DIAGNOSTICS 129PROSTATE CANCER 130TABLE 61 STATUS OF ADVANCED PROSTATE CANCER DIAGNOSTICS 132THYROID CANCER 135TABLE 62 STATUS OF ADVANCED THYROID CANCER DIAGNOSTICS 135SUMMARY OF ADVANCED CANCER DIAGNOSTICS 136TABLE 63 NEXT GENERATION DX TEST SUMMARY BY INDICATION AND BYTECHNOLOGY 136WARFARIN SENSITIVITY 137TABLE 64 IMPORTANCE OF CYP GENES IN DRUG METABOLISM 138TABLE 65 STATUS OF ADVANCED WARFARIN CYP PHARMACOGENETICDIAGNOSTICS 139INFECTIOUS DISEASES 141TUBERCULOSIS 141HOSPITAL ACQUIRED INFECTIONS 142TABLE 66 STATUS OF MRSA AND C. DIFFICILE ADVANCED DIAGNOSTICS 142INFLUENZA 143TABLE 67 STATUS OF INFLUENZA ADVANCED DIAGNOSTICS 144SEXUALLY TRANSMITTED DISEASES 145TABLE 68 STATUS OF CT/NG ADVANCED DIAGNOSTICS 146OTHER INFECTIOUS DISEASES 146NEUROLOGICAL 147ALZHEIMER S DISEASE 147TABLE 69 ALZHEIMER S DISEASE DIAGNOSTICS APPROACHES 148TABLE 70 STATUS OF ALZHEIMER S DISEASE ADVANCED DIAGNOSTICS TESTS 148SCHIZOPHRENIA 149CARDIAC DISORDERS 150CONGESTIVE HEART FAILURE 150TABLE 71 BNP MOLECULAR DIAGNOSTICS TESTS FOR CONGESTIVE HEART FAILURE 151CYSTIC FIBROSIS 152TABLE 72 CYSTIC FIBROSIS ADVANCED DIAGNOSTICS TESTS 153NONINVASIVE PRENATAL SCREENING 154TABLE 73 NEXT GENERATION SEQUENCING BASED PRENATAL DIAGNOSTICSINDUSTRY 155IMMUNE DISORDERS 156HLA TYPING 156TABLE 74 HLA TESTING MARKET 157AUTOIMMUNE TESTING 158CHAPTER 8 BIOCHIPS INDUSTRY 161BIOCHIPS INDUSTRY ACQUISITIONS, 2012 2013 161TABLE 75 ACQUISITIONS IN THE BIOCHIPS INDUSTRY, 2012 161BIOCHIPS INDUSTRY STRATEGIC ALLIANCES, 2012 2013 164MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012 2013 164TABLE 76 MICROARRAY INDUSTRY STRATEGIC ALLIANCES, 2012 165LOAC INDUSTRY STRATEGIC ALLIANCES, 2012 2013 169TABLE 77 LOC/NGS INDUSTRY STRATEGIC ALLIANCES, 2012 169LOAC INDUSTRY 177LOAC INDUSTRY OVERVIEW 178TABLE 78 LOAC COMPETITOR LANDSCAPE 178LAdidas Trefoil Hi White ShoesOAC INSTRUMENT INDUSTRY 179TABLE 79 LEADING LOAC INSTRUMENT MANUFACTURERS 180LOAC DNA ANALYZER INDUSTRY 181TABLE 80 FORENSIC APPLICATIONS FOR LOAC BASED DNA ANALYZERS 181LOAC DIAGNOSTICS INDUSTRY 182TABLE 81 LOAC DIAGNOSTICS INDUSTRY 182ION CHANNEL SCREENING INDUSTRY 182TABLE 82 ION CHANNEL SCREENING INDUSTRY 183DIGITAL PCR INDUSTRY 183TABLE 83 DIGITAL PCR INDUSTRY 184INFLUENTIAL UNIVERSITIES IN THE LOAC INDUSTRY 185TABLE 84 LOC UNIVERSITY SPIN OFFS 185ROLE OF LOAC ACQUISITIONS IN LIFE SCIENCES INDUSTRY 186TABLE 85 LEADING LIFE SCIENCE COMPANIES ACQUISITIONS IN LOAC 186NEXT GENERATION SEQUENCING INSTRUMENT INDUSTRY 187TABLE 86 NEXT GENERATION SEQUENCING INSTRUMENT COMPANIES:COMMERCIAL PHASE 187MICROARRAY INDUSTRY 188SUSPENSION BEAD/GEL BASED MICROARRAY INDUSTRY 188TABLE 87 SUSPENSION BEAD/GEL BASED MICROARRAY INDUSTRY 188LABEL FREE DETECTION INDUSTRY 189TABLE 88 LABEL FREE DETECTION INDUSTRY 189NANOARRAY INDUSTRY 191TABLE 89 NANOARRAY INDUSTRY 191PEPTIDE MICROARRAY INDUSTRY 191TABLE 90 KEY PEPTIDE MICROARRAY COMPANIES 192ANTIBODY MICROARRAY INDUSTRY 192TABLE 91 KEY ANTIBODY MICROARRAY COMPANIES 193ANTIBODY REAGENTS INDUSTRY 194TABLE 92 MARKET SHARE FOR KEY ANTIBODY REAGENTS COMPANIES 194BIOCHIPS DIAGNOSTICS INDUSTRY 195MULTIPLEX PROTEIN DIAGNOSTICS INDUSTRY 195TABLE 93 MULTIPLEX PROTEIN IN VITRO DIAGNOSTICS COMPANIES 195CIRCULATING TUMOR CELL INDUSTRY 197TABLE 94 CTC BIOCHIPS INDUSTRY 198PRENATAL DIAGNOSTICS INDUSTRY 199TABLE 95 NORTH AMERICAN TEST COSTS AND PRICES ($) 200TABLE 96 NEXT GENERATION SEQUENCING BASED, NONINVASIVE PRENATALDIAGNOSTIC MARKET SHARE BY TEST REVENUE, 2013 (%) 201TABLE 97 NONINVASIVE PRENATAL DIAGNOSTICS POTENTIAL FUTURECOMPETITORS 202POC CD4 COUNTING INDUSTRY 202TABLE 98 POC CD4 INDUSTRY 203AGRICULTURAL INDUSTRY 203TABLE 99 BIOCHIPS BASED COMPANIES IN AGRICULTURAL INDUSTRY 204CHINA S BIOCHIP INDUSTRY 205TABLE 100 CHINA BIOCHIP INDUSTRY 206CHAPTER 9 BIOCHIPS MARKETS 210DRIVING FORCES FOR BIOCHIPS GROWTH 210TABLE 101 BIOCHIPS KEY MARKET GROWTH DRIVING FORCES 210GLOBAL BIOCHIPS MARKET 211TABLE 102 GLOBAL VALUE OF BIOCHIPAdidas Trefoil Hi White Shoes PRODUCTS BY TYPE, THROUGH 2018 ($MILLIONS) 211TABLE 103 GLOBAL VALUE OF BIOCHIP MARKET BY END USE INDUSTRY, THROUGH2018 ($ MILLIONS) 212TABLE 104 BIOCHIPS SUBSTRATE MATERIALS 213TABLE 105 GLOBAL VALUE OF BIOCHIP MARKET BY SUBSTRATE MATERIAL,THROUGH 2018 ($ MILLIONS) 213DNA MICROARRAY MARKETS 214DNA MICROARRAY MARKET BY END USE INDUSTRY 214TABLE 106 GLOBAL VALUE OF DNA MICROARRAYS BY END USE, THROUGH 2018 ($MILLIONS) 214DNA MICROARRAY MARKET BY ANALYSIS TYPE 216TABLE 107 GLOBAL VALUE OF DNA MICROARRAYS BY ANALYSIS TYPE, THROUGH2018 ($ MILLIONS) 216FIGURE 10 ENTRIES TO MIRNA DATABASE, 2002 2013 (NO. OF MIRNAS) 218DNA MICROARRAY MARKET BY SUBSTRATE MATERIAL 219TABLE 108 GLOBAL VALUE OF DNA MICROARRAYS BY SUBSTRATE MATERIAL,THROUGH 2018 ($ MILLIONS) 219PROTEIN MICROARRAYS MARKETS 219INTRODUCTION 219TABLE 109 COMPETITIVE PLATFORMS BY MULTIPLEXING DENSITY 220PROTEIN MICROARRAYS MARKET BY END USE INDUSTRY 221TABLE 110 GLOBAL VALUE OF PROTEIN MICROARRAYS BY END USE, THROUGH2018 ($ MILLIONS) 221PROTEIN MICROARRAYS MARKET BY SUBSTRATE MATERIAL 222TABLE 111 GLOBAL VALUE OF PROTEOMIC MICROARRAYS BY SUBSTRATEMATERIAL, THROUGH 2018 ($ MILLIONS) 223TABLE 112 COATED MICROARRAY SLIDE MARKET PRINCIPAL COMPETITORS 223PROTEOMIC MICROARRAYS MARKET BY ARRAY TYPE 224TABLE 113 GLOBAL VALUE OF PROTEOMIC ARRAYS BY ARRAY TYPE, THROUGH2018 ($ MILLIONS) 224EMERGING MICROARRAYS MARKETS 225EMERGING MICROARRAYS MARKET BY TECHNOLOGY 225TABLE 114 GLOBAL VALUE OF EMERGING ARRAYS, BY ARRAY TYPE, THROUGH2018 ($ MILLIONS) 225EMERGING MICROARRAYS MARKETS BY END USE INDUSTRY 226TABLE 115 GLOBAL VALUE OF EMERGING ARRAYS BY END USE, THROUGH 2018 ($MILLIONS) 226EMERGING ARRAYS MARKET BY SUBSTRATE TYPE 227TABLE 116 GLOBAL VALUE OF EMERGING ARRAYS BY SUBSTRATE MATERIAL,THROUGH 2018 ($ MILLIONS) 227LOAC MARKETS 227GENOMICS LOAC MARKET BY END USE INDUSTRY 227TABLE 117 GLOBAL VALUE OF GENOMICS LAB ON A CHIP BY END USER INDUSTRY,THROAdidas Trefoil Hi White ShoesUGH 2018 ($ MILLIONS) 228GENOMICS LOAC MARKET BY SUBSTRATE TYPE 229TABLE 118 GLOBAL VALUE OF GENOMICS LOAC BY SUBSTRATE MATERIAL,THROUGH 2018 ($ MILLIONS) 229PROTEOMICS LOAC MARKET BY END USE INDUSTRY 230TABLE 119 GLOBAL VALUE OF PROTEOMIC LAB ON A CHIP BY END USERINDUSTRY, THROUGH 2018 ($ MILLIONS) 230PROTEOMICS LOAC MARKET BY SUBSTRATE TYPE 232TABLE 120 GLOBAL VALUE OF PROTEOMICS LOAC BY SUBSTRATE MATERIAL,THROUGH 2018 232NGS MARKETS 233NGS MARKETS BY END USER INDUSTRY 233TABLE 121 GLOBAL VALUE OF NGS MARKET BY END USER INDUSTRY, THROUGH2018 ($ MILLIONS) 233NGS MARKET BY SUBSTRATE TYPE 234TABLE 122 GLOBAL VALUE OF NGS BY SUBSTRATE MATERIAL, THROUGH 2018 ($MILLIONS) 234NGS MARKETS BY TEST COMPLEXITY 235TABLE 123 GLOBAL VALUE OF NGS BY TEST COMPLEXITY, THROUGH 2018 ($MILLIONS) 235BIOCHIPS DIAGNOSTICS MARKETS 237INTRODUCTION 237DIAGNOSTICS MARKET BY BIOCHIP TYPE 237TABLE 124 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY BIOCHIP TYPE, THROUGH2018 ($ MILLIONS) 238TABLE 125 ADOPTION RATE FOR DNA MICROARRAYS IN DIAGNOSTICS 240DIAGNOSTICS MARKET BY INDICATION 241TABLE 126 GLOBAL VALUE OF DIAGNOSTICS MARKET, BY INDICATION, THROUGH2018 ($ MILLIONS) 241DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL 245TABLE 127 GLOBAL VALUE OF DIAGNOSTICS MARKET BY SUBSTRATE MATERIAL,THROUGH 2018 ($ MILLIONS) 246CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE 246TABLE 128 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY BIOCHIP TYPE,THROUGH 2018 ($ MILLIONS) 247CANCER DIAGNOSTICS MARKET BY INDICATION 248TABLE 129 GLOBAL VALUE OF CANCER DIAGNOSTICS MARKET BY INDICATION,THROUGH 2018 ($ MILLIONS) 248TABLE 130 2013 STATUS OF PROTEOMICS BASED DIAGNOSTICS FOR CANCERAPPLICATIONS 249BIOCHIPS GEOGRAPHIC MARKETS 251GEOGRAPHY MARKET SUMMARY 251TABLE 131 GLOBAL VALUE OF BIOCHIPS MARKET BY GEOGRAPHY, THROUGH 2018($ MILLIONS) 251MICROARRAY MARKET BY GEOGRAPHY 252TABLE 132 GLOBAL VALUE OF MICROARRAY MARKET BY GEOGRAPHY, THROUGH2018 ($ MILLIONS) 253LOAC MARKET BY GEOGRAPHY 254TABLE 133 GLOBAL VALUE OF LOAC MARKET BY GEOGRAPHY, THROUGH 2018 ($MILLIONS) 254NGS MARKET BY GEOGRAPHY 255TABLE 134 GLOBAL VALUE OF NGS MARKET BY GEOGRAPHY, THROUGH 2018 ($MILLIONS) 255CHAPTER 10 BIOCHIPS PATENTS 258MICROARRAY PATENTS 258TABLE 135 DNA MICROARRAY PATENTS BY REGION, 2002 258TABLE 136 MICROARRAY RELATED PROTEOMICS PATENTS BY REGION, 2002 259LOAC PATENTS 259TABLE 137 LOAC RELATED PROTEOMICS PATENTS BY REGION, 2002 260CLINICAL NEXT GENERATION SEQUENCING PATENTS 260CLINICAL NGS PATENTS SUMMARY 260TABLE 138 CLINICAL NEXT GENERATION SEQUENCING PATENTS, 2002 261CLINICAL NGS PATENTS BY INDICATION 261TABLE 139 CLINICAL NEXT GENERATION SEQUENCING PATENTS BY INDICATION,2002 261CHAPTER 11 COMPANY PROFILES 2643QBD 26420/20 GENE SYSTEMS, INC.